Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis - PubMed
a day ago
- #targeted-therapy
- #chemotherapy
- #ovarian-cancer
- 分子靶向治疗联合化疗对铂类耐药/难治性卵巢癌(PROC)患者具有显著获益
- 贝伐珠单抗、索拉非尼及adavosertib联合化疗方案可显著改善患者总生存期(OS)和无进展生存期(PFS)
- Adavosertib+吉西他滨方案会增加3-4级不良事件(AEs)发生风险，但总体可控
- 基于贝伐珠单抗的联合方案(特别是紫杉醇+贝伐珠单抗)在疗效与安全性之间达到最佳平衡
- 对于不适合抗血管生成治疗的患者，拓扑替康+索拉非尼可作为替代治疗方案